| Lemur tyrosine kinase 2 has a tumor-inhibition function in human glioblastoma by regulating the RUNX3/Notch pathway. | Lemur tyrosine kinase 2 has a tumor-inhibition function in human glioblastoma by regulating the RUNX3/Notch pathway.
Zhang L, Luo P, Mao X, Sun J, Wei J, Yang Y, Zhang Y, Jiang X. | 08/20/2023 |
| Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. | Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
Bencze J, Szarka M, Bencs V, Szabó RN, Smajda M, Aarsland D, Hortobágyi T., Free PMC Article | 11/21/2020 |
| silencing of LMTK2 suppresses the proliferation and invasion of hepatocellular carcinoma cells. | Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling.
Zhao G, Song Y, Dong L, Shi H, Li H, Yang L, Wang J. | 06/20/2020 |
| LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may contribute to Alzheimer's disease. | LMTK2 binds to kinesin light chains to mediate anterograde axonal transport of cdk5/p35 and LMTK2 levels are reduced in Alzheimer's disease brains.
Mórotz GM, Glennon EB, Gomez-Suaga P, Lau DHW, Robinson ED, Sedlák É, Vagnoni A, Noble W, Miller CCJ., Free PMC Article | 04/25/2020 |
| Our findings demonstrate that circLMTK2 functions as a tumour promoter in GC through the miR-150-5p/c-Myc axis and could thus be a prognostic predictor and therapeutic target for GC. | circLMTK2 acts as a sponge of miR-150-5p and promotes proliferation and metastasis in gastric cancer.
Wang S, Tang D, Wang W, Yang Y, Wu X, Wang L, Wang D., Free PMC Article | 04/18/2020 |
| both BIM and BCL2 proteins are regulated by LMTK2 in a GSK3beta- and PP1A-dependent manner. | Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members.
Conti A, Majorini MT, Fontanella E, Bardelli A, Giacca M, Delia D, Mano M, Lecis D. | 08/12/2017 |
| Mutation of the di-acidic export motif led to endoplasmic reticulum retention of LMTK2, and an increase in protein half-life. | Signal dependent ER export of lemur tyrosine kinase 2.
Butler EC, Bradbury NA., Free PMC Article | 06/28/2016 |
| Lemur Tyrosine Kinase-2 (LMTK2), negatively regulates androgen-dependent and androgen-independent prostate cancer cell proliferation. In addition, LMTK2 also negatively regulates the androgen receptor transcriptional activity. | Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy.
Shah K, Bradbury NA., Free PMC Article | 04/4/2016 |
| Data indicate that Lemur tyrosine kinase 2 (LMTK2) localizes at the plasma membrane and co-immunoprecipitates with cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells. | LMTK2-mediated phosphorylation regulates CFTR endocytosis in human airway epithelial cells.
Luz S, Cihil KM, Brautigan DL, Amaral MD, Farinha CM, Swiatecka-Urban A., Free PMC Article | 11/8/2014 |
| The results indicate that lemur tyrosine kinase 2 is an integral membrane protein in which both the amino and carboxyl termini are exposed to the cytoplasm. Moreover, this topology places the kinase active site within the cytoplasm. | Determination of the membrane topology of lemur tyrosine kinase 2 (LMTK2) by fluorescence protease protection.
Nixon A, Jia Y, White C, Bradbury NA., Free PMC Article | 03/30/2013 |
| We describe a new signalling pathway within the nervous system that links cdk5/p35 with phosphatase-1C and which has implications for a number of neuronal functions and neuronal dysfunction | Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity.
Manser C, Vagnoni A, Guillot F, Davies J, Miller CC. | 05/26/2012 |
| Low LMTK2 expression is associated with the development of prostate cancer. | Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Harries LW, Perry JR, McCullagh P, Crundwell M., Free PMC Article | 02/5/2011 |
| Meta-analysis of gene-disease association. (HuGE Navigator) | Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J, Sun J., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease.
Bao BY, Pao JB, Lin VC, Huang CN, Chang TY, Lan YH, Lu TL, Lee HZ, Chen LM, Ting WC, Hsieh CJ, Huang SP. | 06/30/2010 |
| Data show that downregulation of myosin VI expression results in a significant reduction in PSA and VEGF secretion in LNCaP cells, and the intracellular targeting seems to involve myosin VI-interacting proteins, GIPC and LMTK2 and Dab2. | Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.
Puri C, Chibalina MV, Arden SD, Kruppa AJ, Kendrick-Jones J, Buss F., Free PMC Article | 02/8/2010 |
| Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) | See all PubMed (2) articlesInherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y, Turner AR, Jin T, Zhang Z, Adolfsson J, Wiklund F, Zheng SL, Isaacs WB, Grönberg H, Xu J. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.
Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. | 05/6/2009 |
| role of the segment KLHY in binding with protein phosphatase 1 | Characterization of the protein phosphatase 1-binding motifs of inhibitor-2 and DARPP-32 by surface plasmon resonance.
Lin TH, Tsai PC, Liu HT, Chen YC, Wang LH, Hsieh FK, Huang HB. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (9) articlesValidation of genome-wide prostate cancer associations in men of African descent.
Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR. Susceptibility loci associated with prostate cancer progression and mortality.
Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans.
Hooker S, Hernandez W, Chen H, Robbins C, Torres JB, Ahaghotu C, Carpten J, Kittles RA. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, Lu TL, Lan YH, Liu CC, Yang WH, Lee HZ, Hsieh CJ, Bao BY. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men.
Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, Gao Z, Kim ST, Isaacs WB, Shen MC, Gao YT, Hoover RN, Xu J. Prostate cancer risk associated loci in African Americans.
Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, Sun J, Isaacs SD, Wiley KE, Kim ST, Hsu FC, Wu W, Torti FM, Walsh PC, Chang BL, Isaacs WB. Established prostate cancer susceptibility variants are not associated with disease outcome.
Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Grönberg H, Xu J. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations.
Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, Haiman CA. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Grönberg H, Isaacs W, Zheng S. | 03/25/2009 |
| Results show that BREK is critical for the transition of endocytosed membrane vesicles from early endosomes to recycling endosomes and also suggest an involvement of myosin VI in this pathway. | BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking.
Inoue T, Kon T, Ohkura R, Yamakawa H, Ohara O, Yokota J, Sutoh K. | 01/21/2010 |
| Genome-wide association study of gene-disease association. (HuGE Navigator) | Multiple newly identified loci associated with prostate cancer susceptibility.
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. | 04/3/2008 |
| Myosin VI and LMTK2 are required for the transport of cargo, such as the Transferrin Receptor, from early endosomes to the endocytic recycling compartment. | Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment.
Chibalina MV, Seaman MN, Miller CC, Kendrick-Jones J, Buss F., Free PMC Article | 01/21/2010 |
| BREK, Brain Enriched Kinase, is a new member of the family of protein serine/threonine kinases; plays important roles in NGF-TrkA signalling in the brain [BREK] | Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling.
Kawa S, Fujimoto J, Tezuka T, Nakazawa T, Yamamoto T. | 01/21/2010 |
| Cprk is expressed in a number of tissues but is enriched in brain and muscle; Cprk displays catalytic activity in kinase assays and is itself phosphorylated by cdk5/p35; Cdk5/p35 inhibits cprk activity | Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase.
Kesavapany S, Lau KF, Ackerley S, Banner SJ, Shemilt SJ, Cooper JD, Leigh PN, Shaw CE, McLoughlin DM, Miller CC., Free PMC Article | 01/21/2010 |
| KPI-2 is a kinase with sites to associate with PP1C and Inh2 to form a regulatory complex that is localized to membranes | A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2.
Wang H, Brautigan DL. | 01/21/2010 |